SGLT2 inhibitors can also reverse LV remodeling by reducing Na + and NHE-1 receptor activity in cardiomyocytes to slow myocardial fibrosis and cardiac hypertrophy [43]. The gene discussed is SLC5A2; the disease is cardiac hypertrophy.